CV Sciences（CVSI）株式概要CVサイエンシズ社は、北米でハーブサプリメント、ヘンプベースのカンナビジオール（CBD）、植物由来の食品を開発、製造、マーケティング、販売している。 詳細CVSI ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間55.9%増加しました。 リスク分析意味のある時価総額がありません ( $6M )キャッシュランウェイが1年未満である US市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るCVSI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.02940.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-22m54m2016201920222025202620282031Revenue US$8.5mEarnings US$892.9kAdvancedSet Fair ValueView all narrativesCV Sciences, Inc. 競合他社Integrated BioPharmaSymbol: OTCPK:INBPMarket cap: US$7.8mSynergy CHCSymbol: NasdaqCM:SNYRMarket cap: US$4.4mCCA IndustriesSymbol: OTCPK:CAWWMarket cap: US$3.4mMannatechSymbol: NasdaqCM:MTEXMarket cap: US$11.0m価格と性能株価の高値、安値、推移の概要CV Sciences過去の株価現在の株価US$0.02952週高値US$0.1052週安値US$0.023ベータ0.451ヶ月の変化-18.54%3ヶ月変化-19.23%1年変化-0.34%3年間の変化-30.50%5年間の変化-92.08%IPOからの変化-94.45%最新ニュースお知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025お知らせ • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025お知らせ • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025お知らせ • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025お知らせ • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.お知らせ • Feb 20CV Sciences, Inc. announced that it has received $1.2 million in fundingCV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000お知らせ • Nov 22CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million.CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions.お知らせ • Nov 08CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024お知らせ • Aug 27CV Sciences, Inc. Launches +PlusHLTHCV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies.お知らせ • Aug 07CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024お知らせ • Jun 08CV Sciences, Inc. Elects Bill Mccorkle as DirectorsCV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors.お知らせ • May 10CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024お知らせ • Apr 13CV Sciences, Inc., Annual General Meeting, Jun 03, 2024CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors.お知らせ • Mar 26CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives.お知らせ • Mar 22CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024お知らせ • Dec 14CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million.CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023.お知らせ • Nov 10CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023お知らせ • Sep 06CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health.お知らせ • Aug 03CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023お知らせ • May 10CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023お知らせ • Jan 19CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.お知らせ • Jan 06CV Sciences, Inc. Announces Launch of ProCBD™ Product LineCV Sciences, Inc. announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners. Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review. Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.お知らせ • Nov 06CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product LineCV Sciences, Inc. announced the launch of PlusCBD™ Pet, a full line of hemp extracts formulated exclusively for dogs and cats. Made with the same trusted hemp extracts used in CV Sciences’ CBD products, PlusCBD™ Pet is available in 250mg and 500mg formats with pet friendly flavors, including beef, chicken, peanut butter and salmon, as well as unflavored. PlusCBD™ Pet will be sold across the Company’s natural and online retail channels, with plans to expand into the pet specialty channel and food, drug and mass retail channel.お知らせ • Oct 07CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product LaunchesCV Sciences, Inc. announced a comprehensive refresh of its PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products over the next 45 days. The new PlusCBD™ brand is a refinement and modernization that includes new packaging with a contemporary color palette and a post-modern aesthetic to relay each product’s value proposition across the product offering. The 30+ new product launch includes eight new, innovative products featuring extra strength gummies and maximum strength softgels. The refreshed PlusCBD™ packaging features its new, prominently displayed CV Sciences logo, transparent QR code labeling linked to lab reports to assure customers of the unrivaled quality, and the milligrams of CBD per serving on the label.お知らせ • Jul 24CV Sciences, Inc. to Report Q2, 2020 Results on Aug 06, 2020CV Sciences, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020株主還元CVSIUS Personal ProductsUS 市場7D-1.7%3.6%2.2%1Y-0.3%-14.0%31.1%株主還元を見る業界別リターン: CVSI過去 1 年間で-14 % の収益を上げたUS Personal Products業界を上回りました。リターン対市場: CVSIは、過去 1 年間で31.1 % のリターンを上げたUS市場を下回りました。価格変動Is CVSI's price volatile compared to industry and market?CVSI volatilityCVSI Average Weekly Movement22.7%Personal Products Industry Average Movement9.0%Market Average Movement7.3%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: CVSIの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CVSIの weekly volatility ( 23% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201043Joe Dowlingwww.cvsciences.comCVサイエンシズ社は、北米でハーブサプリメント、ヘンプベースのカンナビジオール（CBD）、植物由来の食品を開発、製造、マーケティング、販売している。同社は、PlusCBD、PlusHLTH、Cultured Foods、Lunar Foxのブランド名で、栄養補助食品、美容ケア、特殊食品、ペット用品などのヘルスケア市場分野で、ウェブサイト、一部の流通業者、実店舗およびモルタル小売店、一部の電子小売店を通じて製品を提供している。同社は以前はCannaVest Corp.として知られていたが、2016年1月にCV Sciences, Inc.に社名を変更した。CV Sciences, Inc.は2010年に法人化され、カリフォルニア州サンディエゴに本社を置いている。もっと見るCV Sciences, Inc. 基礎のまとめCV Sciences の収益と売上を時価総額と比較するとどうか。CVSI 基礎統計学時価総額US$5.80m収益（TTM）-US$958.00k売上高(TTM)US$13.79m0.4xP/Sレシオ-6.1xPER（株価収益率CVSI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CVSI 損益計算書（TTM）収益US$13.79m売上原価US$7.04m売上総利益US$6.75mその他の費用US$7.71m収益-US$958.00k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0049グロス・マージン48.97%純利益率-6.95%有利子負債／自己資本比率112.3%CVSI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 10:18終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CV Sciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Pablo ZuanicCantor Fitzgerald & Co.Michael GrondahlNorthland Capital MarketsMichael LaveryPiper Sandler Companies2 その他のアナリストを表示
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.
お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
お知らせ • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.
お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
お知らせ • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.
お知らせ • Feb 20CV Sciences, Inc. announced that it has received $1.2 million in fundingCV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000
お知らせ • Nov 22CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million.CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions.
お知らせ • Nov 08CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024
お知らせ • Aug 27CV Sciences, Inc. Launches +PlusHLTHCV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies.
お知らせ • Aug 07CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024
お知らせ • Jun 08CV Sciences, Inc. Elects Bill Mccorkle as DirectorsCV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors.
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024
お知らせ • Apr 13CV Sciences, Inc., Annual General Meeting, Jun 03, 2024CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors.
お知らせ • Mar 26CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives.
お知らせ • Mar 22CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024
お知らせ • Dec 14CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million.CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023.
お知らせ • Nov 10CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023
お知らせ • Sep 06CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health.
お知らせ • Aug 03CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023
お知らせ • Jan 19CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.
お知らせ • Jan 06CV Sciences, Inc. Announces Launch of ProCBD™ Product LineCV Sciences, Inc. announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners. Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review. Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.
お知らせ • Nov 06CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product LineCV Sciences, Inc. announced the launch of PlusCBD™ Pet, a full line of hemp extracts formulated exclusively for dogs and cats. Made with the same trusted hemp extracts used in CV Sciences’ CBD products, PlusCBD™ Pet is available in 250mg and 500mg formats with pet friendly flavors, including beef, chicken, peanut butter and salmon, as well as unflavored. PlusCBD™ Pet will be sold across the Company’s natural and online retail channels, with plans to expand into the pet specialty channel and food, drug and mass retail channel.
お知らせ • Oct 07CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product LaunchesCV Sciences, Inc. announced a comprehensive refresh of its PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products over the next 45 days. The new PlusCBD™ brand is a refinement and modernization that includes new packaging with a contemporary color palette and a post-modern aesthetic to relay each product’s value proposition across the product offering. The 30+ new product launch includes eight new, innovative products featuring extra strength gummies and maximum strength softgels. The refreshed PlusCBD™ packaging features its new, prominently displayed CV Sciences logo, transparent QR code labeling linked to lab reports to assure customers of the unrivaled quality, and the milligrams of CBD per serving on the label.
お知らせ • Jul 24CV Sciences, Inc. to Report Q2, 2020 Results on Aug 06, 2020CV Sciences, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020
